Hope S. Rugo, MD, on Clinical Implications of Using Pembrolizumab Plus Olaparib for TNBC

Posted: Monday, February 12, 2024

Hope S. Rugo, MD, of the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the practical clinical considerations of findings from the KEYLYNK-009 trial. This study compared the use of pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with pembrolizumab plus chemotherapy for patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC).

---